Pliant Therapeutics Reports an Initiation of P-IIb Trial (BEACON-IPF) for Bexotegrast to Treat Idiopathic Pulmonary Fibrosis
Shots:
- The company initiates the P-IIb trial evaluating bexotegrast (160 or 320mg) in patients with IPF. Additionally, ~270 patients are expected to be enrolled in the trial
- The 1EP of the study is an assessment of the change from baseline in absolute forced vital capacity (FVC) mL at 52wk. while the 2EPs incl. the measurement of time to disease progression (≥10% absolute decline from baseline in FVCpp, respiratory-related hospitalization, or all-cause mortality), change from baseline in absolute FVC on or not on background therapies, change from baseline in patient-reported measurements of symptoms
- The company also developed PLN-1474 for NASH with liver fibrosiss & initiates the P-I study of PLN-101095 (dual-selective inhibitor of αvß8 & αvß1 integrins) for solid tumor
Ref: GlobeNewswire | Image: Pliant
Related News:- Novartis Collaborates with Pliant Therapeutics to Develop Therapies for NASH and Fibrotic Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
